门性高血压的药理疗法
Yu Jun Wong1, Juan G Abraldes2
1Liver Unit, Division of Gastroenterology, University of Alberta, Edmonton, Canada; Liver Unit, Division of Gastroenterology, University of Alberta, 1-38 Zeidler Ledcor Centre, 8540 112 Street Northwest, Edmonton, Alberta T6G 2X8, Canada.
门高血压是肝硬化进展的关键因素,其病理生理学和药理疗法被审查. 该审查涵盖了病因和非病因治疗,包括β-阻断剂,以及在肝硬化患者中管理这种疾病的新兴替代方案.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 胃肠病学 胃肠病学
- 临床药理学 临床药理学
背景情况:
- 门高血压是不补偿性肝硬化的主要驱动因素.
- 了解其病理生理学对于有效的患者管理至关重要.
研究的目的:
- 为了审查在肝硬化中门门高血压的病理生理学.
- 讨论药理治疗的理由和证据.
- 探索新兴的治疗替代方案.
主要方法:
- 对门高血压现有研究的文献综述.
- 对药理学治疗策略的分析,包括β-阻断剂.
- 对新型治疗方法的证据综合.
主要成果:
- 门高血压显著影响肝硬化进展.
- 药物治疗方法,特别是非选择性β-阻断剂,具有定义的作用.
- 新兴疗法对未来的管理有希望.
结论:
- 有效的门高血压管理对于预防肝硬化不补偿至关重要.
- 目前的药理选择,如β-阻断剂,是有价值的,但有局限性.
- 对新型治疗方法的持续研究对于改善患者的治疗结果至关重要.
更多相关视频
09:37Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats
Published on: August 1, 2018
04:00Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension
Published on: November 15, 2024
相关概念视频
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Esophageal Varices-I: Introduction
